Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Medical Laboratory Technology Journal
Ilya Bizin
N.N. Petrov Institute of Oncology
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : medical laboratory technology journal

 1 
New Candidate Predisposition Genes for Hereditary Breast Cancer: SLIT3, CREB3, USP39 Kirill Zagorodnev; Alexandr Romanko; Anna P. Sokolenko; Ilya Bizin; Ekaterina S. Kuligina
Medical Laboratory Technology Journal Vol. 7 No. 1 (2021): June
Publisher : Poltekkes Kemenkes Banjarmasin Jurusan Analis Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (292.528 KB) | DOI: 10.31964/mltj.v7i1.401

Abstract

Breast cancer is the most common type of malignant neoplasm in women. BRCA1 and BRCA2 are the most commonly mutated genes, but only up to 30% of hereditary breast cancer cases are attributed to alterations in these genes. A large proportion of genetic causes of hereditary breast cancer remains unknown. Thus, the search for new hereditary mutations and establishing a genetic alteration in each case of hereditary breast cancer is a clinically significant task; be the goal of our research. Next-generation sequencing (NGS) allows for simultaneous analysis of hundreds to thousands of genes at one time. We analyzed the genetic material of 49 patients of the northwest Russian population with clinical signs of hereditary breast cancer and identified new mutations associated with hereditary breast cancer. Research results show two missense mutations - SLIT3 p.Arg154Cys, CREB3 p.Lys157Glu, and truncating mutation - USP39 c.*208G>C. Research conclusion; The identified mutations can explain only a tiny fraction of hereditary breast cancer cases (0.7% to 1.1%). The next step to increase the practical value of the detected alterations should be the analysis of biological characteristics of tumors in carriers of these mutations that can potentially become a target for chemotherapy.
Co-Authors Alexandr Romanko Anna P. Sokolenko Ekaterina S. Kuligina Kirill Zagorodnev